Navigation Links
Potential Drug Target For Treating Cocaine Abuse Found

A substance similar to a drug used in the treatment of Parkinson's disease blocks the stimulating effects of cocaine and could potentially be used to develop drug therapy for cocaine abuse, new research shows.

In an article published in the February 23, 2005, issue of The Journal of Neuroscience, Jonathan Katz and his colleagues at the National Institute on Drug Abuse (NIDA) report the results of experiments showing that mice treated with a substance similar to the drug benztropine did not show any of the typical hyperactive behavior when later injected with cocaine. This effect wore off after a day.

Cocaine produces intense feelings of euphoria by increasing the amount of dopamine that is sent from one neuron to another within the brain reward system. Dopamine signals pleasure and reward by binding to receptors on the receiving neurons, after which it is reabsorbed for later use by a protein that transports it back into the sending neuron. But cocaine blocks the mechanism that transports dopamine, causing it to build up and send an unceasing message of pleasure ?the cocaine high.

Researchers have long searched for "a molecule that would block cocaine's effects on the transporter without inhibiting the transporter by itself," notes Eric Nestler, chair of psychiatry at the University of Texas Southwestern Medical Center in Dallas.

"This article reports early studies with just such a compound." Although the results are preliminary, this breakthrough shows that it may be possible to develop drugs that block cocaine's stimulating effects, and perhaps its power to addict, Nestler says.

Researchers previously thought that different chemicals that prevent the reabsorption of dopamine would all have the same stimulating effect on the brain. The new study shows this may not be true. "In fact, the interaction between dopamine trans-porters and the substances that bind to them may depend on the chemical structure of those substances," say s NIDA's Amy Newman, who synthesized the compound. The researchers found that their novel drug made contact with transporters slowly ?about 10 times slower than cocaine ?which, they speculate, may be why it does not have a stimulating effect.

Between 2 million and 3.2 million people in the United States ?about 1 percent of the population - use cocaine, according to estimates. Of this number, more than 550,000 are crack users. In 2002, 1.5 million Americans were thought to be dependent on or abusing cocaine. "Cocaine is capable of destroying not only the lives of those addicted, but also the lives of those around them," says Katz. "An effective treatment for cocaine addiction would be of immeasurable help to these individuals and their families."


'"/>

Source:Society For Neuroscience


Related biology news :

1. Novel Enzyme Shows Potential As An Anti-HIV Target
2. Potential Cure for Lymphoma in HIV patients
3. Potential treatments for neurofibromatosis
4. Stem Cell Research Shows Potential for Replacing Tissue Damaged in Heart Attacks
5. Potential vaccine developed for deadly leishmaniasis disease
6. Potential heart benefit found in stem cells
7. First-ever Compounds To Target Only Metastatic Cells Are Highly Effective Against Breast, Prostate, And Colon Cancers
8. Affymetrix and ParAllele Launch Industrys Most Comprehensive Product Line for Targeted Genotyping
9. Targeting a key enzyme with gene therapy reversed course of Alzheimers disease in mouse models
10. New Therapeutic Target Identified In Inherited Brain Tumor Disorder
11. Targeted drug delivery achieved with nanoparticle-aptamer bioconjugates
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/6/2017)... Calif. , Jan. 5, 2017  Delta ID ... its iris scanning technology for automotive at CES® 2017. ... GNTX ) to demonstrate the use of iris ... identify and authenticate the driver in a car, and ... during the driving experience. Delta ID and ...
(Date:12/22/2016)... -- As part of its longstanding mission to improve genetic literacy ... released its latest children,s book, titled The One ... topics of inheritance and variation of traits that are part ... school classrooms in the US. The book ... Killoran , whose previous book with 23andMe, You ...
(Date:12/19/2016)... TORONTO , 19 de diciembre de 2016  Mosaic Biomedicals ... el desarrollo acelerado de MSC-1, un anticuerpo humanizado que se espera ... en 2017, con múltiples sitios previstos a lo largo de Europa ... MSC-1 ... factor inhibidor de leucemia (LIF), una citoquina pleiotrópica que se sobreexpresa ...
Breaking Biology News(10 mins):
(Date:1/19/2017)... 19, 2017 /PRNewswire -- WuXi AppTec, a leading ... and technology platform, today announced that it has ... preclinical drug discovery contract research organization (CRO). After ... wholly-owned subsidiary of WuXi, and will continue to ... greater services. The acquisition will further strengthen WuXi,s ...
(Date:1/19/2017)... , ... January 19, 2017 ... ... advanced software solutions for pharmaceutical research and development (R&D), today announced the ... omic data analysis and interpretation for the rapidly evolving field of precision ...
(Date:1/19/2017)... GAITHERSBURG, Md. , Jan. 19, 2017 ... Inc., a privately-held immunotherapeutics company targeting infectious diseases, ... for the merger of PharmAthene and Altimmune in ... Venture Fund, HealthCap, Truffle Capital and Redmont Capital. ... diversified immunotherapeutics company with four clinical stage and ...
(Date:1/19/2017)... 2017 AquaBounty Technologies, Inc. (AIM: ABTU; NASDAQ: ... aquaculture and a majority-owned subsidiary of Intrexon Corporation (NYSE: ... the listing of its common shares on the NASDAQ ... "AquaBounty,s listing on NASDAQ represents an important ... to the U.S. markets as we advance plans for ...
Breaking Biology Technology: